CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer

Immune checkpoint blockade (ICB) improves outcomes in non-small cell lung cancer (NSCLC) though most patients progress. There are limited data regarding molecular predictors of progression. In particular, there is controversy regarding the role of CDKN2A loss-of-function (LOF) in ICB resistance. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutiontov, Stanley I., Turchan, William Tyler, Spurr, Liam F., Rouhani, Sherin J., Chervin, Carolina Soto, Steinhardt, George, Lager, Angela M., Wanjari, Pankhuri, Malik, Renuka, Connell, Philip P., Chmura, Steven J., Juloori, Aditya, Hoffman, Philip C., Ferguson, Mark K., Donington, Jessica S., Patel, Jyoti D., Vokes, Everett E., Weichselbaum, Ralph R., Bestvina, Christine M., Segal, Jeremy P., Pitroda, Sean P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501138/
https://www.ncbi.nlm.nih.gov/pubmed/34625620
http://dx.doi.org/10.1038/s41598-021-99524-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501138/
https://www.ncbi.nlm.nih.gov/pubmed/34625620
http://dx.doi.org/10.1038/s41598-021-99524-1

Ejemplares similares